Citations

Clear

4847 citation(s) found for "Yu, Eric".

Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti–CD20-based Biological Therapy
Sohani, Aliyah R. , Giri, Sharmila, Pitcher, Brandelyn N., Chadburn, Amy , Said, Jonathan , Bartlett, Nancy L. , Czuczman, Myron S., Martin, Peter , Rosenbaum, Cara A. , Leonard, John P. , Cheson, Bruce D. , Bartlett, Nancy L , Maurer, Matthew J. , Jung, Sin‐Ho , Hsi, Eric D.

Mayo Clinic

American Journal of Surgical Pathology | November 2, 2020 | Volume: 45 | Issue: 3 | Pages: 384-393

10.1097/pas.0000000000001609 | PMID 33136585 Get It

Follicular lymphoma (FL) is an indolent B-cell neoplasm of germinal center origin. Standard treatment regimens consist of anti-CD20 therapy with or without chemotherapy. While high response rates to initial therapy are common, patients ultimately relapse or have progressive disease. Clinical risk factors such as the Follicular Lymphoma International Prognostic Index (FLIPI) have been identified, but there is a need for prognostic and predictive biomarkers. We studied markers of lymphoma cells and tumor microenvironment by immunohistochemistry in tissue samples from patients enrolled in 1 of 4 phase 2 trials of anti–CD20-based biological therapy for previously untreated grades 1 to 2 or 3A FL. Results were correlated with progression-free survival (PFS) and PFS status at 24 months. The 4 trials included 238 patients (51.1% male, median age: 55 y) with stage III, IV, or bulky stage II disease. By FLIPI, 24.6% had low-risk, 56.8% had intermediate-risk, and 18.6% had high-risk disease. The outcome differed significantly for patients treated with lenalidomide and rituximab (CALGB 50803) compared with the other 3 trials (median: PFS not reached vs. 3.0 y, hazard ratio=3.47, 95% confidence interval: 2.11-5.72); therefore, data were stratified by clinical trial (CALGB 50803 vs. all others) and adjusted for FLIPI risk group. Among 154 patients with available tissue, interfollicular BCL6 positivity, interfollicular CD10 positivity, and elevated Ki67 proliferation index ≥30% within neoplastic follicles were each associated with inferior PFS and a high risk of the early event by PFS status at 24 months. We identify promising biomarkers for FL risk stratification that warrant further validation in phase 3 trials.
S0495 The Safety Profile of Tegaserod 6 Mg BID in Irritable Bowel Syndrome With Constipation in Women
Lacy, Brian E. , Chey, William D. , Shah, Eric D. , Lacy, Brian E. , Chang, Lin , Brenner, Darren M.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S247-S247

10.14309/01.ajg.0000704028.06576.5a Get It

S0494 Efficacy of Tegaserod 6 mg BID for Treating Irritable Bowel Syndrome With Constipation in Women
Lacy, Brian E. , Chey, William D. , Shah, Eric D. , Chang, Lin , Brenner, Darren M.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S247-S247

10.14309/01.ajg.0000704024.89100.6d Get It

S0492 Tegaserod 6 Mg BID for Treating Abdominal Pain and Bloating in Women With Irritable Bowel Syndrome With Constipation but Without Cardiovascular Risk Factors: A Pooled Analysis of 4 Clinical Trials
Lacy, Brian E. , Chey, William D. , Shah, Eric D. , Chang, Lin , Brenner, Darren M.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S246-S246

10.14309/01.ajg.0000704016.06499.ec Get It

S0266 Sulindac and Eflornithine Combination Delays the Need for Lower Gastrointestinal Surgery in Familial Adenomatous Polyposis: CPP FAP-310 Trial
Lynch, Patrick M. , Samadder, N. Jewel , Hüneburg, Robert , Lim, Ramona M., Boytim, Michelle L., Du, Wei , Bruckheimer, Elizabeth, Cohen, Alfred, Balaguer, Francesc , Stoffel, Elena M. , Burke, Carol A. , Dekker, Evelien , Cutsem, Eric Van , Wise, Paul E. , Du, Wei, Church, James M.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2020 | Volume: 115 | Issue: 1 | Pages: S129-S129

10.14309/01.ajg.0000703112.43206.46 Get It

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
Fernández-Martínez, Aranzazu , Krop, Ian E. , Hillman, David W. , Polley, Mei‐Yin C. , Huebner, Lucas J. , Hoadley, Katherine A. , Shepherd, Jonathan H. , Tolaney, Sara M. , Henry, N. Lynn , Dang, Chau T. , Harris, Lyndsay N. , Berry, Donald A. , Hahn, Olwen, Hudis, Clifford A. , Perou, Charles M. , Polley, Mei-Yin , Huebner, Lucas , Hoadley, Katherine A , Tolaney, Sara , Henry, N Lynn , Berry, Donald , Hudis, Clifford , Winer, Eric , Partridge, Ann H , Perou, Charles M , Hillman, David W , Parker, Joel S. , Winer, Eric P. , Partridge, Ann H. , Carey, Lisa A. , Shepherd, Jonathan H. , Fernandez-Martinez, Aranzazu

Mayo Clinic

Journal of Clinical Oncology | October 23, 2020 | Volume: 38 | Issue: 35 | Pages: 4184-4193

10.1200/jco.20.01276 | PMID 33095682 Get It

PURPOSE CALGB 40601 assessed whether dual versus single human epidermal growth factor receptor 2 (HER2) –targeting drugs added to neoadjuvant chemotherapy increased pathologic complete response (pCR). Here, we report relapse-free survival (RFS), overall survival (OS), and gene expression signatures that predict pCR and survival. PATIENTS AND METHODS Three hundred five women with untreated stage II and III HER2-positive breast cancer were randomly assigned to receive weekly paclitaxel combined with trastuzumab plus lapatinib (THL), trastuzumab (TH), or lapatinib (TL). The primary end point was pCR, and secondary end points included RFS, OS, and gene expression analyses. mRNA sequencing was performed on 264 pretreatment samples. RESULTS One hundred eighteen patients were randomly allocated to THL, 120 to TH, and 67 to TL. At more than 7 years of follow-up, THL had significantly better RFS and OS than did TH (RFS hazard ratio, 0.32; 95% CI, 0.14 to 0.71; P = .005; OS hazard ratio, 0.34; 95% CI, 0.12 to 0.94; P = .037), with no difference between TH and TL. Of 688 previously described gene expression signatures, significant associations were found in 215 with pCR, 45 with RFS, and only 22 with both pCR and RFS (3.2%). Specifically, eight immune signatures were significantly correlated with a higher pCR rate and better RFS. Among patients with residual disease, the immunoglobulin G signature was an independent, good prognostic factor, whereas the HER2-enriched signature, which was associated with a higher pCR rate, showed a significantly shorter RFS. CONCLUSION In CALGB 40601, dual HER2-targeting resulted in significant RFS and OS benefits. Integration of intrinsic subtype and immune signatures allowed for the prediction of pCR and RFS, both overall and within the residual disease group. These approaches may provide means for rational escalation and de-escalation treatment strategies in HER2-positive breast cancer.
Comparison of reconstructive techniques following oncologic intraarticular resection of proximal humerus
Houdek, Matthew T. , Bukowski, Brandon R., Athey, Alexander G., Elhassan, Bassem T. , Rose, Peter S. , Barlow, Jonathan D. , Sanchez-Sotelo, Joaquin, Houdek, Matthew T , Morrey, Mark E. , Wagner, Eric R. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Journal of Surgical Oncology | October 23, 2020 | Volume: 123 | Issue: 1 | Pages: 133-140

10.1002/jso.26271 | PMID 33095924 Get It

AbstractIntroductionThe proximal humerus is a common site of primary and metastatic disease in the upper extremity. Historically, the goal of a hemiarthroplasty reconstruction was to provide a stable platform for hand and elbow function, with limited shoulder function. Techniques utilizing a reverse endoprosthesis (endoprosthetic replacement [EPR]) and allograft‐prosthetic composite (APC) have been developed; however, there is a paucity of comparative studies.MethodsA total of 83 (42 females, 41 males) patients undergoing an intraarticular resection of the humerus were reviewed. Reconstructions included 30 reverse and 53 hemiarthroplasty; including hemiarthroplasty EPR (n = 36) and APC (n = 17), and reverse EPR (n = 20) and APC (n = 10).ResultsReverse reconstructions had improved forward elevation (85° vs. 44°, p < .001) and external rotation (30° vs. 21°; p < .001) versus a hemiarthroplasty. Reverse reconstructions had improved American Shoulder and Elbow Surgeons scores (65 vs. 57; p = .01) and Musculoskeletal Tumor Society 93 scores (72 vs. 63; p < .001) versus hemiarthroplasty. Subluxation of the reconstruction was a common (n = 23, 27%), only occurring in hemiarthroplasty patients (EPR [n = 13, 36%] and APC [n = 10, 59%]).ConclusionThe current series highlights the improved functional outcome in patients undergoing reconstruction with a reverse arthroplasty compared to the traditional hemiarthroplasty. Currently reverse shoulder arthroplasty (APC or EPR) is our preferred methods of reconstruction in this patient population.
Prognostic Factors in Patients with Differentiated Thyroid Cancers Metastatic to the Cervical Spine
Puccinelli, Cassandra L., Abel, Kathryn M. Van , Kasperbauer, Jan L. , Janus, Jeffrey R. , Ryder, Mabel , Moore, Eric J. , Yin, Linda X , Van Abel, Kathryn M , Kasperbauer, Jan , Moore, Eric J , Ryder, Mabel , Yin, Linda X. , Price, Daniel L.

Mayo Clinic

The Laryngoscope | October 23, 2020 | Volume: 131 | Issue: 5 | Pages: No page available

10.1002/lary.29174 | PMID 33095932 Get It

ObjectivesThe spine is the most common site of bone metastases in differentiated thyroid cancer (DTC). The role of surgery in the management of cervical spine (C‐spine) metastases (CSpM) has not been adequately explored.MethodsThis is a retrospective cohort study at a tertiary referral center from 2002 to 2018. Inclusion criteria were pathologic diagnosis of DTC and imaging/pathologic diagnosis of CSpM. Statistical analysis utilized t tests for continuous variables and χ2 tests for categorical variables. Survival analysis was conducted using Kaplan–Meier curves with univariate and multivariate Cox regressions.ResultsFifty patients with DTC and CSpM were identified. Of those, 16 underwent surgical resection of the C‐spine, whereas 34 did not. The most common presenting symptom was neck pain (N = 37, 74%). Patients in the surgery group were more likely to report a subjective improvement of symptoms (P < .01) and to have local (P < .01) and systemic (P = .04) disease control. Five‐year overall survival was 44.7% for the surgery group (95% confidence interval [CI]: 17.1–69.3) and 11.1% (95% CI: 2.1–28.8) for the nonsurgery group (P = .01). The strongest risk factor for improved overall survival after C‐spine metastasis was local disease control at the C‐spine (multivariate hazard ratio [HR] = 0.32, 95% CI: 0.12–0.85, P = .02). Surgical intervention was significantly associated with improved survival on both univariate (HR = 0. 35, 95% CI: 0.15–0.82, P = .02) and multivariate (HR = 0.37, 95% CI: 0.14–0.98, P = .04) analysis.ConclusionSurgical management of CSpM in differentiated thyroid cancers is associated with significantly improved local disease control and overall survival. Referral to spine surgeons should be considered after diagnosis.Level of EvidenceIV. Laryngoscope, 131:E1741–E1747, 2021